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Abstract
Purpose This study aims to obtain consensus statements required for the development of clinical guidelines for the use of
benzodiazepines (BZDs) and Z-drugs for the management of primary insomnia in adults in Saudi Arabia.
Methods Three rounds of the e-Delphi technique using a Bristol Online Survey (BOS) were conducted between May
and August 2018. The Director of the Saudi Sleep Medicine Group helped recruit the country’s sleep medicine
experts. Snowballing was used to forward invitation emails, information sheets, and the survey to known sleep
medicine experts and physicians deemed to be interested in the field. All participants’ details were anonymised except
to the researcher.
Results Fifteen experts from four different regions and specialities in Saudi Arabia participated in Round 1. Twenty-
one statements originated from participants’ responses. In Round 2, there were 17 respondents and 16 of the state-
ments obtained the required consensus of 70% or higher. Eleven experts participated in Round 3 and eight statements
received 100% agreement, two received 91%, and six received 82%. Having obtained the required consensus of 80%
or higher in Round 3, these 16 statements fulfilled the criteria to be included in future guidelines. The five statements
that failed to attain the required consensus were rejected as inappropriate for inclusion in Saudi Arabian clinical
guidelines.
Conclusions The items that achieved the required consensus can be included in future guidelines for the use of BZDs and Z-drugs
in the treatment of primary insomnia in adults to standardize best practices in sleep medicine in Saudi Arabia.
Keywords Benzodiazepines . Z-drugs . Saudi Arabia . Clinical guidelines . Primary insomnia . e-Delphi technique
Note: This manuscript or essence of its contents is not previously
published in partial or full in the website or printed journal.
Key Messages
Findings from this study will help to develop guidelines for the
prescription of BDZs and Z-drugs for the treatment of primary insomnia
in Saudi Arabia. Additionally, with guidelines in place, patient outcomes
following the judicious use of hypnotic drugs will improve.
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Introduction
Insomnia and other sleep disorders are amongst the most
neglected illnesses by medical practitioners [1]. The various
studies that have attempted to address the prevalence of sleep
disorders in the Kingdom of Saudi Arabia are limited [2].
Nevertheless, according to the available data, it is evident that
sleep disorders are increasingly becoming prevalent amongst
Saudis, yet sleep medicine services in Saudi Arabia remain
below the level of services offered in developed countries [3].
A recent study reported the prevalence of insomnia with the
presence of daytime dysfunction in 57% of Saudi adults at-
tending primary care services [1]. Various obstacles have been
cited as the factors that hinder the progress of speciality in
sleep medicine in Saudi Arabia. They include a lack of spe-
cialists, few trained technicians, and insufficient funding [2].
Furthermore, awareness about insomnia and other sleep dis-
orders as well as their consequences is low amongst healthcare
authorities and practitioners [1]. This lack of knowledge is
attributed to the poor education received by medical students
who transition into practice [4]. The low awareness is also
widespread amongst the general public, health care workers
and authorities, and the insurance companies in Saudi Arabia
[2]. With such low awareness and knowledge about insomnia,
there are no evidence-based clinical guidelines regarding the
management of the illness amongst Saudis.
Overall, two treatment options have been accepted widely
for the management of insomnia. These methods include cog-
nitive behavioural therapy for insomnia (CBT-I) and hypnotic
medications [5, 6]. Comparatively, hypnotic drugs act faster
than CBT-I and are thus preferred by patients [6]. Some of the
drugs used in the treatment of insomnia are benzodiazepines
and Z-drugs. Despite being indicated for this disorder, benzo-
diazepines have the potential to trigger dependence with con-
sequent rebound and withdrawal symptoms upon sudden dis-
continuation [6]. In contrast to benzodiazepines, Z-drugs are
more selective in their action and have a lower tendency to
develop dependence and withdrawal symptoms [6]. They still,
however, have similar adverse effects associated with benzo-
diazepines as they can cause anterograde amnesia, sedation,
impaired balance, and complex sleep-related behaviour [6, 7].
Hypnotic risks and side effects have led to the development
of many guidelines for diagnosing and managing chronic in-
somnia in different countries [8–12]. Whilst benzodiazepines
and Z-drugs have proven benefits in the management of pri-
mary insomnia, contradiction and differing opinions surround
their use [13]. This is because there is no clear evidence guid-
ing the judicious use of these drug classes for the treatment of
insomnia, especially in countries like Saudi Arabia where
there is an overall low awareness of sleep medicine [2]. In
addition, many physicians in Saudi Arabia do not follow in-
ternational guidelines because they lack awareness of them or
think they are culturally inappropriate for use in Saudi Arabia
[14]. It is, therefore, imperative that Saudi Arabia has its own
guidelines for treating and managing insomnia and other sleep
disorders, which are consistent with its own history and
culture.
Consensus methods can be used to come up with guiding
principles to eliminate the barriers associated with contradic-
tory opinions [15]. One such approach is the Delphi tech-
nique, a structured process designed to arrive at a consensus
of choice or judgement following responses by a panel of
experts to rounds of questionnaires on a topic for which there
is little evidence [16, 17]. This method is particularly useful in
situations where several dissenting opinions and contradic-
tions surround a subject [15, 16], as in the use of Z-drugs
and benzodiazepines in the management of primary insomnia
in Saudi Arabia. Guidelines developed by this means are like-
ly to be accepted widely by medical practitioners in the coun-
try involved [15].
Methods
The purpose of this study was to use the e-Delphi method to
create a set of statements that could be used to develop a
clinical guideline for the use of Z-drugs and benzodiazepines
for managing primary insomnia (difficulty to sleep without a
known cause) [11] amongst adults in Saudi Arabia.
Delphi technique
The consensus process incorporated three rounds e-Delphi
technique [16], using Bristol online survey, which took place
betweenMay and August 2018. Ethical approval (number 17/
15) was obtained from University of Reading Ethics
Committee (UREC), United Kingdom. Experts in sleep med-
icine in Saudi Arabia, defined as those who are specialists in
sleep medicine (accredited by the Saudi Commission for
Health Specialties) or work in sleep clinics or have experience
of treating patients with insomnia, were recruited with the help
of the Saudi Sleep Medicine Group. Snowballing was also
used as participants were asked to forward an invitation email
including an information sheet and a link to the survey to other
physicians and/or experts in sleep disorders when they
thought might be interested in participating. Participation in
the first-round questionnaire was considered as consent to
participate in the study. All participants’ details were
anonymised, except to the first author.
Round 1
The first round online questionnaire included open-ended
questions to solicit some information from participants [18]
about their current practices and thoughts for managing
primary insomnia, which might be appropriate for
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inclusion in consensus statements. The objective of the
study and some specific instructions were provided for
participants. Some demographic details were asked as well.
The survey was piloted with five people (three pharmacists
and two physicians) not participating in the work or in the
main e-Delphi study. The purpose of the pilot was to en-
sure feasibility of the procedure, clarity of the questions,
and to estimate the time for completing the questionnaire.
No amendments were requested in Round 1. Potential par-
ticipants were sent the questionnaire by email and the sur-
vey was accessible for 1 month. Responses from each
question of the first round were aggregated, and then fre-
quencies and percentages were calculated when appropriate
to identify the most frequent answers. All data were tabu-
lated together with qualitative responses as feedback for
participants in the next round.
Round 2
Before completing the second questionnaire, each partici-
pant reflected on his/her answers compared to those of
other participants. The researcher refined all responses
from Round 1 and created items for ranking based on
the participants’ answers and best-practice guidelines for
managing primary insomnia in adult patients. Twenty-one
statements were prepared for circulation in Round 2. A
second online questionnaire was sent to participants,
who were asked to forward it to other experts regardless
of whether they had participated in Round 1. Participants
were asked to rank each item on a 1 to 5 Likert scale
(definitely disagree to definitely agree) that best represent-
ed their opinions about the criteria that they wanted to be
included in future Saudi Arabia guidelines. They were
also asked to briefly comment on their reasons for choos-
ing a specific grade (1–5). The consensus was defined as
70% or higher agreement. The questionnaire was piloted
with three physicians to ensure the procedure’s feasibility
and the clarity of the statements. Of the 21 statements sent
in the e-Delphi pilot, three were clarified according to the
participants’ comments. All of those three physicians par-
ticipated in Round 2, and the survey was accessible for
3 weeks.
Round 3
Responses from Round 2 were collated and refined.
Participants received feedback with ratings summarised by
the researcher so that they could revise their judgements. A
third questionnaire was then sent, which included 16 state-
ments. Participants were asked to specify which of these
should be included or excluded in future guidelines.
Statements that were excluded because they did not achieve
70% agreement in the second round were provided for
participants in a separate question, and they were asked if
any statement should be reinstated and included in the guide-
lines. Consensus was defined as 80% or higher agreement
(Fig. 1 shows e-Delphi process to achieve consensus on state-
ments to be included in future guidelines). The survey was
accessible for a month.
Results
Round 1
Fifteen participants from the four largest regions in Saudi
Arabia (East, West, South, and Central) participated in
Round 1. Eight of the participants stated that they were qual-
ified from outside Saudi Arabia and the rest were from inside.
Details of demographic data are provided in Table 1.
Responses from this round lead to forming 21 statements to
be ranked.
Round 2
Twenty-one statements were sent for ranking in Round 2.
Seventeen responses were received and all who participated
in this round were specialised or trained in sleep medicine.
The data were analysed using in the BOS that showed the
percentage that each statement achieved. Each statement that
achieved 70% or higher from summation of score 4 and 5 on
the Likert scale was considered as agreement. Sixteen state-
ments made the cutoff for consensus agreement and five state-
ments failed to achieve the 70% agreement in this round.
Feedback from this round about the statements, each item’s
rankings, and the participants’ choices were prepared and cir-
culated to the expert panel, allowing each participant to reflect
on his/her answers in relation to those of other participants
before completing the third questionnaire.
Round 3
In Round 3, 11 responses were received and all participants
were experts in sleep medicine (specialised, trained in sleep
medicine, or working in sleep clinics). Table 1 shows the
demographic details and characteristics of the participants in
each round.
All statements (16) that were returned to the expert
panel in this round made the cutoff of 80% or higher
consensus agreement. Table 2 shows the statements sent
in Round 3 and the percentage agreements achieved.
None of the excluded statements achieved the percentage
agreement to be reinstated. Table 3 shows the statements
that did not achieve consensus in Rounds 2 and 3.
Anonymity was retained during the study.
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Discussion
Clinical practice guidelines form critical frameworks for the
summary and translation of continually changing evidence
from research into actual practice [19]. They assist practi-
tioners in making reasonable clinical decisions about appro-
priate healthcare for specific clinical circumstances [20, 21].
This study aimed to obtain consensus on items required for
developing clinical guidelines for using benzodiazepines and
Z-drugs for managing insomnia amongst adults in Saudi
Arabia. After three rounds of review, the e-Delphi technique
generated 16 statements to be included in future guidelines.
Five statements failed to reach the 80% level of consensus
needed and were, therefore, excluded from the guidelines.
The e-Delphi technique was considered the most appropriate
method considering the lack of national clinical guidelines
currently in the Saudi healthcare literature. This method facil-
itated the consolidation of information from experts in several
Round 3: CG development 
- Summary report containing potential final statements
- Obtain consensus on guideline statements (include or do not include) (agreement 
= 80% or more) 
Round 2: Reflect on the practice
- Feed the information from Round 1 back to participants
- Percentage of 70 % or higher for final round for agreement. 
- Rank importance of statements (strongly disagree to strongly agree)
Round 1: Raising awareness
- Collect participants' demographic data 
- Collate participants practices and opinion
- Information gathering on current practice for managing primary insomnia  
Fig. 1 e-Delphi process to
achieve consensus on statements
to be included in future guidelines
Table 1 Demographic data and characteristics of participants (Rounds 1, 2, and 3)
Round 1 Round 2 Round 3
Gender Male: 14
Female: 1
Male: 16
Female: 1
Male: 9
Female: 2
Expert in sleep medicine Yes: 8
No: 7
Yes: 17
No: 0
Yes: 11
No: 0
Years of practice as a sleep medicine
specialist or in a sleep clinic
< 5 years: 5
5–10 years: 4
> 10 years: 6
< 5 years: 8
5–10 years: 3
> 10 years: 6
< 5 years: 4
5–10 years: 3
> 10 years: 4
Region South: 6
East: 1
West: 2
Central: 6
South: 4
East: 1
West: 1
Central: 11
South: 4
East: 1
West: 1
Central: 5
Place of practice University hospital/sleep centre: 4
Ministry of health: 7
Private: 2
Military hospital: 2
University hospital/sleep centre: 7
Ministry of health: 6
Private: 2
King Faisal specialist hospital
and research centre: 2
University hospital/sleep centre: 5
Ministry of health: 4
Private: 1
King Faisal specialist hospital
and research centre: 1
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locations and omitted the burden of travelling around the
country [15, 16]. Because the researcher could provide feed-
back after each round, encourage participants to reflect on their
answers, and assess them compared to other answers, the e-
Delphi technique enhanced an interactive exchange of informa-
tion between participants [16]. The expert panel agreed that the
use of benzodiazepines and/or Z-drugs for primary insomnia
should be accompanied by a documented diagnosis. The panel
also agreed that before initiating any intervention, it is impera-
tive to conduct a thorough assessment of the patient to identify
all the possible causes of disturbed sleep and to identify all the
salient exacerbating factors so that appropriate treatment is in-
dicated as necessary [22]. The panel also came to the consensus
that CBT-I is useful and recommended as a first-line treatment
for primary insomnia. The management of primary insomnia
amongst the adult population in Saudi Arabia should centre, at
least initially, on cognitive and behavioural non-
pharmacological approaches. These strategies include sleep hy-
giene, straightforward advice, relaxation techniques, counsel-
ling, and behavioural therapy [8]. Behavioural and psycholog-
ical interventions have been proven to be useful for all adults as
well as for chronic users of hypnotic drugs [8]. When the initial
behavioural or psychological treatment proves ineffective, other
approaches should be considered and the patient evaluated for
potential occult comorbidities [11].
Thus, the expert consensus is that pharmacological interven-
tions should be considered when non-pharmacological treat-
ments were unsuccessful and alternated from one class to the
other only if they prove unsuccessful. Importantly, the choice of
benzodiazepines or Z-drugs should be guided by the treatment
goal, symptomatology, patient preference, past response pat-
terns, cost, comorbidities, interactions with concomitantly ad-
ministered medications, side effects, contraindications, and the
availability of other treatment options [11]. Although short- to
intermediate-acting benzodiazepines or Z-drugs are recom-
mended for adults with primary insomnia [6, 11], all of the
expert opinions reviewed by the study emphasised that these
drugs should be used for short-term use only.
Due to dependency and tolerance associated with most
hypnotic medications, the panel recommended a maximum
treatment duration of 2 weeks. Repeat or additional prescrip-
tions for benzodiazepines or Z-drugs should be avoided be-
cause their long-term use can complicate prognoses [22].
Furthermore, it was agreed that dosage tapering should be
considered for patients withdrawing from these drugs and that
CBT-I is known to be effective in helping medication tapering
and discontinuation [11].
Table 2 Statements achieving 80% agreement or higher, to be included
in future guidelines
Statements
100% agreement
1. When using benzodiazepines or Z-drugs to treat primary insomnia, the
diagnosis should be recorded
2. Cognitive Behavioural Therapy for Insomnia (CBT-I) is effective and
recommended for primary insomnia as first-line treatment
3. Benzodiazepines or Z-drugs are recommended for primary insomnia for
short-term use only
4. When prescribing benzodiazepines or Z-drugs beyond the maximum
treatment period, reasons for continuing should be documented
5. When prescribed benzodiazepines or Z-drugs are ineffective, alternative
medicines should be used
6.When initiating benzodiazepines or Z-drugs for a patient, inform the patient
that it will be for a limited duration
7. When prescribing benzodiazepines or Z-drugs for long term, patients
should be reviewed regularly, at least every 4–6 weeks
8. When withdrawing patients on long-term use of benzodiazepines or
Z-drugs, tapering should be considered
91% agreement
1. Extension beyond the maximum treatment period of benzodiazepines or
Z-drugs should not take place without re-evaluating the patient
2. Short-term hypnotic treatment should be supplemented with CBT-I when
possible
82% agreement
1. Sleep hygiene is effective and recommended in the treatment of primary
insomnia as first-line treatment
2. Benzodiazepines and Z-drugs should be used to treat primary insomnia
only when it is severe, disabling, or causing extreme distress
3. Benzodiazepines or Z-drugs should be prescribed in the first instance with
the lowest effective dosage used
4. Benzodiazepines or Z-drugs should not be prescribed for more than
4 weeks
5. Benzodiazepines or Z-drugs should not be prescribed for patients with a
history of addiction or substance abuse
6. Switching from one hypnotic to another should occur only if a patient
experiences adverse effects directly related to a specific agent
Table 3 Statements eliminated
from inclusion in future
guidelines
Statements Percentage
achieved
Short-acting benzodiazepines or Z-drugs are recommended as the first-line pharmacological
treatment for primary insomnia
25
Only Z-drugs (e.g. zolpidem) are recommended as the first-line pharmacological treatment
for primary insomnia
0
When prescribed benzodiazepines or Z-drugs are ineffective, the dose should not be in-
creased
12.5
When prescribed benzodiazepines or Z-drugs are ineffective, the dose should be increased 25
When prescribed benzodiazepines or Z-drugs are ineffective, a combination with other
sedative agents can be used
37
Sleep Breath
The e-Delphi technique further revealed that all the experts
involved were of the opinion that when prescribing benzodi-
azepines and Z-drugs beyond the maximum treatment period,
reasons for continuing should be documented. Long-term
hypnotic therapy may be indicated for individuals with refrac-
tory or severe insomnia or persons with chronic comorbidities
[11]. Consistent follow-up, however, is imperative, preferably
every 4–6 weeks in the initial phase of treatment, to assess
potential side effects, treatment efficacy, and the reason for
continuing the medication [11]. The prescriber should always
ensure that hypnotic medications are reviewed regularly and
all review dates and relevant advice are clearly documented in
the patient’s records [22].
The panel was unanimous that alternative medicines
should be used if the prescribed benzodiazepines or Z-drugs
are deemed to be ineffective. Drugs from other classes are
available to treat primary insomnia, but unlike benzodiaze-
pines and Z-drugs, they work through receptors other than
the benzodiazepine section of the gamma-aminobutyric acid
(GABA-A) receptor [6]. Additionally, the experts agreed that
patients should be informed that using benzodiazepines or Z-
drugs is for a limited duration only. Patient education should
always accompany treatment, particularly if benzodiazepines
and Z-drugs are prescribed. Amongst the many factors that
patients should be informed about are safety concerns, treat-
ment expectations and goals, potential drug interactions and
side effects, alternative treatment modalities including behav-
ioural and cognitive therapy, rebound insomnia, and the pos-
sibility for dosage increments [11].
Over 90% of the responses given recommended that
extension beyond the maximum treatment period for ben-
zodiazepines or Z-drugs should not take place without re-
evaluation of the patient and that short-term hypnotic treat-
ment should be supplemented with CBT-I when possible.
Furthermore, patients should be advised to keep sleep dia-
ries and that, should a relapse occur, the data be used for
long-term re-evaluation [11]. In addition to clinical reas-
sessment of patients, regular administration of survey tools,
such as questionnaires, might be useful in outcome assess-
ment. Findings from such tools would help in informing
subsequent treatment efforts [11].
Most experts consider sleep hygiene a useful treatment mo-
dality and recommend it as a first-line treatment for insomnia.
Even though insomnia patients should follow sleep hygiene
recommendations, there is insufficient evidence to support the
effectiveness of sleep hygiene alone for managing chronic pri-
mary insomnia [11]. For this reason, sleep hygiene should be
combined with other interventions, such as biofeedback thera-
py (educating patients to control involuntary processes in their
body such as muscle tension and blood pressure) [11].
Even though short-acting benzodiazepines or Z-drugs are
recommended as the first-line pharmacological treatment for
primary insomnia [11], the majority of participants rejected this
recommendation to be included in the guidelines. A significant
number of experts believed that benzodiazepines and Z-drugs
should be used to treat primary insomnia only when it is severe,
disabling, or causing extreme distress. A majority of the
panellists also recommended prescribing these drugs in the first
instance at the lowest effective dose. This dose should be used
for maintenance and tapered off as determined by the prognosis
[11]. Further, the specialists said that benzodiazepines or Z-
drugs should not be prescribed for more than 4 weeks as rec-
ommended in the literature [23], and that switching from one
hypnotic to another should be considered only if the patient
experiences adverse effects from the drug they are using [22].
Importantly, most of the responders agreed that benzodiaze-
pines should not be prescribed to known or suspected users of
illicit drugs. According to the literature, exceptions may be
made if the drugs are indicated as part of an opiate detoxifica-
tion programme or prescribed under close monitoring and su-
pervision by psychiatrists on an acute basis [22].
Overall, a consensus was reached for most of the recom-
mendations with significant agreements between rounds. The
e-Delphi technique was well received and external reviewers
contributed extensive comments to support the development
of guidelines. Although the authors believe that the contribu-
tions from the medical experts to the consensus statements are
thoughtful and valuable, this study has some limitations. The
absence of a face-to-face meeting might have deprived experts
from exchanging important information, such as clarification
of reasons for disagreements [24, 25].
Conclusion
With little awareness about sleep disorders and the absence of
evidence-based clinical guidelines on the management of insom-
nia, adults in the Saudi Arabia are at a higher risk of suffering
serious consequences from the condition. It is imperative, there-
fore, that effective guidelines for treating insomnia and sleep
disorders are developed in Saudi Arabia, particularly guidelines
concerning the pharmacological management of primary insom-
nia with benzodiazepines and Z-drugs. Using the e-Delphi tech-
nique, this study developed evidence-based expert clinical opin-
ions for using benzodiazepines and Z-drugs in managing insom-
nia, and such findings based on consensus statements, together
with insomnia advocacy, reviewing service delivery across Saudi
Arabia, and best-practice management of primary insomnia, can
lead to optimal sleep disorder healthcare in Saudi Arabia.
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